Macro True Bio invests 6.37 million to enter the ophthalmology product market.

Teo Yek Ming, the director and manager of Macro True Bio, said today at a press conference that this acquisition will expand its business portfolio to the ophthalmology product industry, beneficial for company growth.

It has rich experience and professional knowledge in the ophthalmology industry, which can help us quickly penetrate new markets.

He revealed that Eye Nation Medical is equipped with necessary licenses, certifications, and compliance systems to help Hong Cheng Shengke deal with regulatory requirements, meet industry standards, and ensure product specifications, thereby reducing legal risks.

Eye Nation Medical was established in 2003, mainly engaged in the trade of diagnostic equipment and related products in the ophthalmic product industry.

The company's CEO, Edmund Lee, stated that the current business model mainly focuses on B2B (business to business), but now plans to sell some products in a B2C (business to consumer) model to reach a broader consumer cohort.

"Currently, we have established approximately 600 networks in public and private sectors, combined with the advantages of Hong Cheng Shengke, we believe we will rapidly grow in the future."

Once the acquisition is completed, Eye Nation Medical will become a subsidiary of Hong Cheng Shengke, holding 70% of the shares, and providing a profit guarantee of 2.6 million Malaysian Ringgit for 2 years.

Ching Chee Pun, Chairman of Hong Cheng Shengke, added that besides internal business growth, the company also considers driving business growth through merger and acquisition activities.

"Our core business mainly involves financial lending and medical care, while internal growth is promising, M&A can further accelerate business growth."

He also revealed that the company has been looking for suitable targets in related fields, and if there is further development, it will be announced to the public in a timely manner.